6831-82-9Relevant articles and documents
Manganese-Mediated C-C Bond Formation: Alkoxycarbonylation of Organoboranes
Van Putten, Robbert,Filonenko, Georgy A.,Krieger, Annika M.,Lutz, Martin,Pidko, Evgeny A.
supporting information, p. 674 - 681 (2021/04/02)
Alkoxycarbonylations are important and versatile reactions that result in the formation of a new C-C bond. Herein, we report on a new and halide-free alkoxycarbonylation reaction that does not require the application of an external carbon monoxide atmosphere. Instead, manganese carbonyl complexes and organo(alkoxy)borate salts react to form an ester product containing the target C-C bond. The required organo(alkoxy)borate salts are conveniently generated from the stoichiometric reaction of an organoborane and an alkoxide salt and can be telescoped without purification. The protocol leads to the formation of both aromatic and aliphatic esters and gives complete control over the ester's substitution (e.g., OMe, OtBu, OPh). A reaction mechanism was proposed on the basis of stoichiometric reactivity studies, spectroscopy, and DFT calculations. The new chemistry is particularly relevant for the field of Mn(I) catalysis and clearly points to a potential pathway toward irreversible catalyst deactivation.
Preparation method of intermediate for synthesizing 3 -oxo -1 -cyclobutane carboxylic acid
-
Paragraph 0031-0034; 0036-0039, (2021/09/29)
The invention discloses a preparation method for synthesizing 3 -oxo -1 -cyclobutane carboxylic acid intermediate 1, 1 - bis (prop -2 -) 3, 3 -dimethoxycyclobutane -1 and 1 - dicarboxylic acid ester (compound I): using potassium isopropoxide as a base, 1 1 -1 as a solvent, and plays an important role in the yield and purity method of 3 the 3 - final product, DMAc which is prepared 1 - or -2 - I
Compounds capable of activating cholinergic receptors
-
, (2008/06/13)
The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.